In a 49-year-old female with schizophrenia, diabetes mellitus, hyperlipidemia, and severe three‑vessel coronary artery disease awaiting coronary artery bypass grafting, who inadvertently received a cumulative 700 mg of aripiprazole long‑acting injection within four days, what is the appropriate management?

Immediate Management of Inadvertent Aripiprazole LAI Overdose

In this patient who received 700 mg aripiprazole LAI within 4 days (rather than the intended monthly schedule), immediate cardiac monitoring with continuous ECG telemetry for at least 48 hours is essential, given her severe three-vessel coronary disease and the documented cardiac risks of aripiprazole, particularly QTc prolongation and arrhythmias. 1, 2, 3

Critical Monitoring Protocol

Cardiovascular Surveillance (Priority #1)

• Continuous ECG monitoring for minimum 48-72 hours to detect QTc prolongation, ventricular arrhythmias, or heart failure exacerbation 1, 2, 3
• Obtain baseline ECG immediately and repeat every 12-24 hours for first 72 hours
• Measure QTc interval specifically—aripiprazole has been associated with severe arrhythmias including ventricular arrhythmia and sudden cardiac death in case reports 2, 3
• Monitor for signs of heart failure decompensation (aripiprazole shows elevated risk for heart failure events, particularly relevant given her severe CAD) 4
• Check troponin levels at baseline and 24 hours to rule out myocardial injury

Metabolic and Hepatic Monitoring

• Baseline and serial liver function tests (AST, ALT, bilirubin, INR) at 24-hour intervals for first 72 hours—acute liver failure has been reported with aripiprazole overdose 5
• Complete blood count with differential to monitor for hemolytic anemia (reported complication of aripiprazole toxicity) 5
• Comprehensive metabolic panel including glucose (given her diabetes), electrolytes (K+, Mg2+, Ca2+—critical for cardiac stability)
• Lipid panel given her hyperlipidemia

Neuropsychiatric Assessment

• Serial mental status examinations every 4-6 hours for first 48 hours
• Monitor for excessive sedation, extrapyramidal symptoms, akathisia, or paradoxical agitation
• Assess for anticholinergic effects (confusion, urinary retention, constipation)

Pharmacokinetic Considerations

The long-acting formulation creates a unique challenge: Aripiprazole LAI has a half-life of approximately 30-47 days, meaning plasma levels will remain elevated for weeks to months. The 700 mg cumulative dose will result in sustained suprapherapeutic levels, but peak toxicity risk is within the first 5-7 days post-injection.

• No specific antidote exists for aripiprazole
• Hemodialysis is ineffective due to high protein binding (>99%)
• Supportive care is the mainstay of management

Specific Management Steps

Days 1-3 (Acute Phase)

1. Admit to telemetry unit (not general medical floor)
2. NPO status initially if altered mental status develops
3. IV access with normal saline at maintenance rate
4. Hold all QTc-prolonging medications if possible
5. Correct any electrolyte abnormalities immediately (target K+ >4.0 mEq/L, Mg2+ >2.0 mg/dL)

Cardiovascular-Specific Interventions

Given her severe three-vessel CAD awaiting CABG 6, 7:

• Cardiology consultation within 24 hours for risk stratification
• Continue her guideline-directed medical therapy for coronary disease (aspirin, statin, beta-blocker if tolerated)
• Do NOT proceed with CABG until aripiprazole levels decline and cardiac stability confirmed (minimum 2-4 weeks, ideally longer)
• If QTc >500 msec or increases >60 msec from baseline: consider magnesium sulfate 2g IV, discontinue other QTc-prolonging agents, increase monitoring frequency

Days 4-14 (Subacute Phase)

• Transition to daily ECG monitoring if stable
• Weekly liver function tests and CBC for 4 weeks
• Monitor for delayed cardiac events (heart failure, arrhythmias can emerge beyond acute phase) 4

Psychiatric Management During Recovery

Do NOT administer additional antipsychotic medications for at least 4-6 weeks given suprapherapeutic aripiprazole levels already present. If acute agitation occurs:

• First-line: environmental modifications, de-escalation techniques
• Second-line: benzodiazepines (lorazepam 1-2 mg IM/PO) rather than additional antipsychotics
• Avoid antipsychotic polypharmacy which increases adverse effects without clear benefit 8

Documentation and Systems Issues

This represents a critical medication safety event requiring:

• Immediate incident report filing
• Root cause analysis to prevent recurrence
• Verification that no further LAI doses are scheduled in pharmacy system
• Clear documentation in all systems: "NO ARIPIPRAZOLE LAI UNTIL [DATE 6 WEEKS FROM LAST DOSE]"

Surgical Planning Implications

Her planned CABG must be postponed 6, 7, 1. The 2024 ESC guidelines recommend CABG for three-vessel disease with diabetes to improve survival 6, but proceeding now would be extremely high-risk:

• Aripiprazole increases perioperative cardiac complications 4
• QTc prolongation increases anesthetic risk
• Potential drug interactions with perioperative medications
• Minimum delay: 6-8 weeks to allow partial drug clearance and cardiac stabilization
• Reassess with cardiology and cardiac surgery when aripiprazole levels decline

Common Pitfalls to Avoid

1. Do not assume "no symptoms = no problem"—cardiac complications can be delayed
2. Do not discharge before 72 hours of monitoring even if initially stable
3. Do not add another antipsychotic thinking the current dose is "inadequate"—she already has suprapherapeutic levels
4. Do not proceed with planned CABG on original timeline
5. Do not rely solely on clinical observation—objective cardiac monitoring is mandatory given her cardiac disease 1, 2, 3

Long-Term Follow-Up

• Outpatient cardiology follow-up at 2 weeks and 6 weeks post-discharge
• Psychiatry follow-up within 1 week of discharge
• When restarting antipsychotic therapy (after 6-8 weeks), consider alternative agent or resume aripiprazole LAI at appropriate monthly dosing with enhanced medication reconciliation protocols 9, 10